News for Palatin Technologies, Inc. (PTN)

PR NewswirePRINCETON, N.J., July 15, 2025 Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatmentCombination of o

Operator: Greetings. Welcome to Palatin's Third Quarter Fiscal Year 2025 Operating Results Conference Call. At this time, all participants are in a listen-only mode.

Palatin Technologies, Inc. (PTN) Q3 2025 - Earnings Conference Call May 14, 2025 11:00 AM ETCompany ParticipantsCarl Spana - CEO and PresidentStephen Wills...

Revenue: No product sales recorded for the quarter ended March 31, 2025, due to the sale of Vyleesi's worldwide rights.Operating Expenses: Total operating expe

PR NewswireCRANBURY, N.J., May 14, 2025 Significant Progress in Obesity and Ocular ProgramsTeleconference and Webcast to be held today - May 14, 2025, at 1

Palatin Technologies (PTNT) reports significant progress in obesity and ocular programs despite financial challenges. Phase 2 obesity study showed a 4.4

PR NewswireCRANBURY, N.J., May 9, 2025 Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vasc

Palatin Technologies (PTN) has revealed encouraging preclinical findings regarding its melanocortin agonists, PL9654 and PL9655, which were presented at the 202

PR NewswireCRANBURY, N.J., May 8, 2025 Company Transitioned onto the OTC PinkCRANBURY, N.J., May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC PI

Palatin Technologies, with the ticker PTN, has recently unveiled positive findings from its Phase 3 MELODY-1 study during the 2025 Association for Research in V

Palatin Technologies (PTNT) unveils groundbreaking Phase 3 MELODY-1 trial results for PL9643 in treating Dry Eye Disease (DED). PL9643 achieved complete

PR NewswireCRANBURY, N.J., May 8, 2025 Updated Phase 3 analysis highlights PL9643 as a potential first-in-class treatment achieving full symptom resolution

Palatin Technologies (PTN) launches a public offering targeting up to $23 million through shares and warrants. Initial proceeds expected at $11.5 millio

\n\nPR NewswireCRANBURY, N.J., May 5, 2025\n\n\n\nTopical melanocortin therapy shows promise for treating glaucomaPL9588 lowers intraocular pressure (IOP) by increasi

Palatin Technologies, identified by the ticker PTN, has revealed encouraging preclinical results showcasing PL9588, an innovative melanocortin receptor agonist.

PR NewswireCRANBURY, N.J., April 29, 2025 Updated Phase 3 analyses position PL9643 as a potential first-in-class therapy achieving full symptom resolution

Palatin Technologies (PTN) has revealed promising updates from its Phase 3 MELODY-1 trial, which assessed the effectiveness and safety of PL9643 in treating dry

Summary: Palatin Technologies (PTN) achieved a breakthrough in its Phase 3 MELODY-1 clinical trial, with PL9643 demons

Palatin Technologies (PTN) has released promising findings from its BMT-801 Phase 2 study that evaluated the effectiveness of different treatments in suppressin